Sanofi has announced that the normal supply of its Apidra insulin may resume around March next year, following a technical glitch the firm has encountered in its manufacturing process in Frankfurt, Germany. Patients on Apidra therapy are advised to switch to a different method or a different brand of insulin.

Related Summaries